Acetazolamide
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Cardiology |
| Polymorphic form | Form II |
| CAS No. | 59-66-5 |
| Reference Product | |
| Injectable Form | Injectable |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Acetazolamide reduces the activity of a protein in your body called carbonic anhydrase. Blocking this protein can help reduce the build-up of certain fluids in the body. Acetazolamide is used in people with certain types of glaucoma to reduce the amount of fluid in the eye, which decreases pressure inside the eye. Acetazolamide is also used as a diuretic ("water pill") in people with congestive heart failure, to reduce the build-up of fluid in the body. This build-up is called edema.Acetazolamide is also used to treat certain types of seizures, and to treat or prevent altitude sickness. Acetazolamide may also be used for purposes not listed in this medication guide.
Polpharma API
- Long experience in in-house commercial manufacturing
- Dedicated production line
- Product meeting the highest quality standards (all single impurities below 0,05%)
- Injection grade
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
